Takeda Filed for US Approval of Diabetes Drug Alogliptin
Filed in archive News , Treatment on January 4, 2008
The Japanese pharmaceutical company - Takeda - announced that it is seeking U.S. approval of its diabetes Drug Alogliptin (SYR-322).
Alogliptin is a diabetes drug that Takeda hopes to replace Actos (Pioglitazone HCl) - another Takeda diabetes drug.
[Alogliptin, or SYR-322, is in a new class of oral agents for the treatment of type 2 diabetes, called DPP-4 inhibitor, regulating blood glucose levels, and the class also includes Merck & Co's Januvia and Novartis AG's Galvus]
According to Takeda spokesman Toshiyuki Ikeuchi:
"We are hoping Alogliptin to boost our diabetes franchise, which is a very important field for us."
The approval process is expected to take about a year."
Find more details from the UK Guardian.
The approval process is expected to take about a year."
Tags: Actos Alogliptin SYR322 Takeda Pharmaceuticals diabetes drug DPP4 inhibitor takeda diabetes+drug
Vote for Takeda Filed for US Approval of Diabetes Drug Alogliptin:
|
Rating: 6.33 out of 3 vote(s) cast.
|
Response from:
Connecting News, Commentaries and Blogs at NineReports.com
Even with Super Bowl, W. Valley economy to struggle ...Blogged about at Takeda Filed for US Approval of Diabetes Drug Alogliptin - daily diabetic, The West Valley can&1;t escape the soft economy in the U.S. but did get a boost from the Super Bowl, said...
Response from:
Trusted.MD Network
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Follow us on Twitter! |
Most Popular
Best of
Blogs, Blogging & Blogosphere
Challenges
Developments
Diabetics' Device
Did you know
Diet
Education
Exercise
Family Matters
Friends
Fun
Information
Information about
Inspiration
Interviews
Lifestyle
Misc
News
Notable
